



Alliance for Clinical Trials in Oncology
Thursday, May 14, 2015
Loews Chicago O'Hare Hotel
3:30 pm - 6:30 pm

Respiratory Committee

Chair: **Everett E. Vokes, MD**
Vice-Chairs: **Dennis Wigle (Surgery)**
Steven Schild (Radiation Oncology)
Pasi Janne (Correlative Science)

1. Committee overview and protocol accrual—Everett Vokes and Xiaofei Wang

- Update on current and planned protocols – Everett Vokes
- NCI Strategic Plan – Everett Vokes
- Status of pending manuscripts – Xiaofei Wang
- Update of NCI Master Protocols – Shakun Malik

2. Stage IV Non-Small Cell Lung Cancer

- CALGB 31002/ACCRU: Erlotinib +/- bevacizumab for NSCLC patients with EGFR mutation – Tom Stinchcombe, Pasi Janne
- SWOG 0819: Chemo-(bev) +/- cetuximab – Lyudmila Bazhenova
- SWOG Squamous Master Protocol in Alliance– Lyudmila Bazhenova, Jeff Engelman, Martin Edelman
- Alk Master Protocol in Alliance – Tom Stinchcombe, Ravi Salgia
- AFT-09: Chemo-Immunotherapy Sequencing – Tom Hensing

New Proposals

- Plasma genotyping for T790M mutations – Geoff Oxnard, Pasi Janne
- PD-1 inhibition for patients with compromised organ function – Becca Heist, Martin Edelman

- **Brain Metastasis Proposal – Priscilla Brastianos**
- 3. **Stage III Non-Small Cell Lung Cancer and Radiation Oncology trials update- Steven Schild**
 - **A-31101 RTOG 1306:** Personalized therapy for inoperable stage III NSCLC - **Ramaswamy Govindan, Olwen Hahn**
 - **AFT-00: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic**
 - **ATF-00:** Chemoradiation plus veliparib –**Tom Stinchcombe, Joe Salama**
 - **Adjuvant Radiotherapy (ART) – Linda Martin, Olwen Hahn, Dennis Wigle**
- 4. **Early Stage Non-Small Cell Lung Cancer and Surgical Studies- Dennis Wigle**
 - **CALGB 140503:** Lobectomy vs. limited resection – **Nasser Altorki**
 - **E 1505:** Intergroup adjuvant bevacizumab study – **Stephen Graziano**
 - **A151216/081105- ALCHEMIST-** Personalized Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer – **Geoffrey Oxnard, Ramaswamy Govindan, Pasi Janne, Dennis Wigle**
 - Current status and addition of PD1 inhibitor arm - **Martin Edelman**
- 5. **Small Cell Lung Cancer**
 - **CALGB 30610:** Limited Stage Intergroup Trial– **Jeffrey Bogart and Greg Masters**
 - **AFT-00: Pembrolizumab vs topotecan for 2nd line SCLC –** **Cathy Pietanza, Ravi Salgia**
 - **Secondary PCI Analysis of 30504 – Joe Salama**
 - **Sunitinib Maintenance and PCI – Neal Ready**
- 6. **Mesothelioma–Robert Kratzke, Hedy Kindler, Arkadiusz Dudek**
 - **CALGB 30901 -** Pemetrexed maintenance Study – **Arkadiusz Dudek**

- New concept: Pembrolizumab in second-line therapy – Hedy Kindler,
Tanguy Seiwert
 - New concept: Palbociclib in Mesothelioma – Mark Klein, Robert Kratzke
7. Correlative Science- Robert Kratzke, Stephen Graziano
- Overview of current projects